Market Overview

From Earlier: Horizon Pharma Announces US Patent for Rayos Tablet

Related HZNP
POZEN Announces Receipt Of Three Patents From The United States Patent And Trademark Office
Horzion Pharma Presents Results of ACTIMMUNE(R) Phase 2 Data, Says Results Show Statistical Significant
Horizon Inks $660M Reverse Merger With Ireland's Vidara (Fox Business)

Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that SkyePharma has received a Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent Application 2012/0177734 entitled "Delayed Release Tablet with Defined Core Geometry" that covers the U.S. approved product RAYOS(R). This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed. The patent scheduled to issue from this application will expire in 2024 for the U.S. patent. After issuance, Horizon plans to list the U.S. patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.

Posted-In: News Legal

 

Related Articles (HZNP)

Around the Web, We're Loving...

Get Benzinga's Newsletters